TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation

Moniek A. De Witte, Gavin M. Bendle, Marly D. Van Den Boom, Miriam Coccoris, Todd D. Schell, Satvir S. Tevethia, Harm Van Tinteren, Elly M. Mesman, Ji Ying Song, Ton N.M. Schumacher

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

40 Citaten (Scopus)


Analogous to the clinical use of recombinant high-affinity Abs, transfer of TCR genes may be used to create a T cell compartment specific for self-Ags to which the endogenous T cell repertoire is immune tolerant. In this study, we show in a spontaneous prostate carcinoma model that the combination of vaccination with adoptive transfer of small numbers of T cells that are genetically modified with a tumor-specific TCR results in a marked suppression of tumor development, even though both treatments are by themselves without effect. These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells.

Originele taal-2Engels
Pagina's (van-tot)2563-2571
Aantal pagina's9
TijdschriftJournal of Immunology
Nummer van het tijdschrift4
StatusGepubliceerd - 15 aug. 2008
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation'. Samen vormen ze een unieke vingerafdruk.

Citeer dit